IMCAS Paris 2025 has once again set the stage for groundbreaking advancements in aesthetic medicine, bringing together top experts, innovators, and industry leaders from around the world.
From January 30 to February 1, 2025, more than 20,000 HCPs gathered at the Palais des Congrès in Paris to attend lectures from 1,000 speakers and explore exhibits from 370 companies.
As one of the most anticipated events in dermatology, plastic surgery, and medical aesthetics, this year’s congress showcased the latest trends, cutting-edge technologies, and expert insights shaping the future of the field.
Key Takeaways
- GLP-1 & Skin Concerns: Rapid weight loss from Ozempic and similar drugs is leading to increased skin laxity, making biostimulators, RF, and thread lifts essential treatments.
- The Shift Toward Natural Aesthetics: Overfilled Syndrome and patient concerns about looking “done” are driving demand for more subtle, regenerative treatments.
- Regenerative Aesthetics on the Rise: Exosomes, PRP, and biostimulators are gaining traction, with plant- and bacterial-based exosome options emerging.
- Holistic Patient Assessments: A full-face, personalized approach is replacing one-size-fits-all treatments, enhancing natural results and patient satisfaction.
- Industry Innovations & Research: Major players like Galderma, Allergan, and Merz unveiled new toxins, treatment frameworks, and research-backed approaches to aesthetics.
Major Topics at IMCAS Paris 2025
Here are some of the key discussions that dominated the conference:
1. The Impact of GLP-1 Agonists on Skin
With the continued popularity of medications like Ozempic and Wegovy, more aesthetic practitioners are seeing increased skin-related concerns from rapid weight loss. In a live survey conducted during one of the symposiums, two-thirds of doctors reported they already treated this indication.
Many practitioners also confirmed that volume loss is not the #1 issue resulting from rapid weight loss. Volume loss is an “easy fix”, as you can easily restore it with volumizing fillers. The real challenge is the skin laxity that these patients also experience. There are multiple treatment options for skin laxity, including collagen biostimulators like Radiesse and Sculptra, radiofrequency (RF) and ultrasound therapies, as well as PRP, thread lifts, and laser treatments.
2. Overfilled Syndrome and Its Effect on Patient Behavior
The ‘Pillow Face Phenomenon,’ along with widely circulated images of overfilled celebrity faces, has contributed to a negative patient perception of dermal fillers, leading many practitioners to experience a decline in patients.
Besides filler migration and other adverse effects, patients are also concerned about “looking done” or, speaking in professional terms, suffering from an Overfilled Syndrome. It’s up to practitioners to make sure this doesn’t happen.
During the IMCAS Teoxane Symposium, Dr. Benji Dhillon shared an ATP framework that can help practitioners avoid OFS. ATP is designed to integrate the science of anatomy, aging, and assessment (A) into clinical decision-making, guiding the choice of technique (T) and product (P) for optimal patient outcomes.
Another tactic that should be implemented, especially if your patients request a larger amount of filler, is patient education. Setting realistic expectations and educating about consequences will ensure your patient leaves your practice as a happy, returning customer.
3. Continuing with the Natural Look
A growing number of practitioners and patients are embracing a more natural aesthetic, moving away from overfilled, frozen expressions. This shift, which has been gaining momentum over the past year, was another major topic at IMCAS. Many experts highlighted new injection techniques, product formulations, and treatment plans designed to restore youthful features while maintaining facial harmony.
Some would even say that the era of volumizing fillers is over, as we now have more biostimulators, regenerative treatments, and toxins with higher diffusion rate, allowing for more natural results.
4. Holistic Approach and More Thorough Assessments
One-size-fits-all treatments are a thing of the past. With new patient assessment techniques, practitioners are now focused on looking at the face as a whole and delivering results that highlight patients’ individual beauty.
To help practitioners deliver even better results, at IMCAS Paris 20 25, Allergan Aesthetics presented their new AA Signature program.
“The AA Signature program addresses the rising demand for a holistic treatment approach and leverages our advanced product portfolio, providing HCPs with access to expert opinions, business support, and comprehensive educational programs – including consumer-focused and AMI-led provider training – that align with individual patient aesthetic goals,” said Mark Wilson, SVP Head of International Commercial, Allergan Aesthetics.
5. Continuing Focus on Regenerative Aesthetics
Regenerative medicine took center stage, particularly the role of exosomes in skin rejuvenation. Clinical applications, like exosome hair loss treatment, were also discussed. IMCAS Paris 2025 also saw several new product launches in this category, reflecting the industry’s shift toward treatments that go beyond traditional fillers and neurotoxins.
However, some of the exosome products are continuing to be controversial, especially those containing human-retrieved exosomes. Thankfully, new options are now available, like plant-based and even bacterial-sourced exosomes, which are both vegan-friendly and have a more stable molecular structure.
Some of these products are already available in our store, including Exojuv, containing plant-derived exosomes.
6. Skin Quality, Skin Quality, Skin Quality!
Beyond structural enhancements, skin quality is now a top priority in aesthetic treatments. The term is not new, but it was previously not in aesthetic HCPs focus.
IMCAS discussions highlighted innovative mesotherapy solutions, bio-remodeling injectables, and advanced skincare protocols to enhance skin texture, hydration, and overall health. Restylane Skinboosters especially stood out, as it’s the only clinically proven injectable that enhances 6 key aspects of skin quality:
- Even Skin Tone – Reduces pigmentation and age spots for a brighter, more radiant complexion.
- Refined Skin Texture – Minimizes the appearance of pores for a smoother surface.
- Enhanced Smoothness – Reduces roughness and optimizes skin texture for a balanced, even feel.
- Deep Hydration – Replenishes moisture for refreshed, luminous skin that reflects light beautifully.
- Scar Reduction – Helps diminish the appearance of acne scars for a clearer complexion.
- Fine Lines & Wrinkle Correction – Smooths fine lines, enhances elasticity, and restores a youthful look.
What’s New from the Industry’s Top Players
Like every year, top manufacturers came prepared with new products, studies, and other updates:
Galderma’s New Toxin Update
New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™), their new toxin brand that is currently getting EU approvals.
At IMCAS 2025, RelabotulinumtoxinA was presented as the first and only ready-to-use liquid neuromodulator developed using PEARL Technology that is optimized for simple volumetric dosing to increase ease of use. It is also supposed to have longer-lasting results (more than 6 months), and a rapid onset from Day 1.
*For patients and practitioners looking for toxins with 1-2 days offset, Dysport is an FDA-approved, available option.
AA Signature Program from Allergan
Launching globally at the IMCAS World Congress 2025, the AA Signature approach focuses on key patient needs commonly seen in clinical practice. The program introduces tailored treatment plans for lift, definition, and skin quality, addressing patient demand for a more holistic approach.
Brand’s research shows that clinics using multimodal treatments see a 68% higher patient retention rate, highlighting the benefits of addressing multiple facial areas in one plan. This can be achieved by a combination of trusted Allergan products, like Juvederm, HArmonyCa, and Botox.
Pillars of Confidence study by Merz Aesthetics
At IMCAS 2025, Merz Aesthetics presented compelling global data from a study involving 15,000 participants, revealing a significant connection between confidence, self-affirmation, and aesthetic treatments.
69% of people surveyed seek aesthetic treatments to reflect how they feel inside, while 72% of respondents said that aesthetic treatments impact how they view themselves. This research underscores the psychological benefits of aesthetic interventions, emphasizing that addressing both physical and emotional aspects of patient care can lead to enhanced patient satisfaction and empowerment in clinical practice.
What’s Next?
Medica Depot is dedicated to bringing you the latest insights about the medical aesthetics industry, as well as access to trending products. If you’re interested in a product you cannot find on our website, please reach out to our Sales team.
